Each year, approximately 110,000 people in the United States are affected by leptomeningeal metastases (LM) — a devastating complication of advanced cancers such as breast, lung, and melanoma. Despite its prevalence, treatment options remain limited, costly, and often ineffective, leaving patients and caregivers with few answers.

In a recent AJMC – The American Journal of Managed Care feature by Mary Caffrey, Plus Therapeutics President and CEO, Marc Hedrick, M.D., discussed how the company is addressing this unmet need.

CNSide® CSF Assay Platform: Detecting and Monitoring Tumor Cells in the CNS

Developed by CNSide Diagnostics, a wholly owned subsidiary of Plus Therapeutics, the CNSide® CSF Assay Platform provides physicians with a powerful tool to detect, enumerate, and monitor tumor cells in the cerebrospinal fluid of patients with CNS malignancies.

In a significant milestone, CNSide recently secured a national coverage agreement with UnitedHealthcare, expanding access to this advanced diagnostic technology for patients and clinicians across the United States.

Together, these innovations — REYOBIQ™ and CNSide® — represent a theranostic approach to CNS oncology: integrating therapy and diagnostics to improve detection, monitoring, and treatment outcomes for patients living with LM and related CNS cancers.

Read the Full AJMC Interview

Can Radiotherapeutics and Early Detection Offer a Breakthrough for Rare CNS Cancer?
By Mary Caffrey, The American Journal of Managed Care
Read the full article

Learn more about our work in CNS oncology: https://lnkd.in/g2ejus4u
Discover our ongoing clinical research: https://www.respect-trials.com
Visit CNSide Diagnostics: https://cnside-dx.com